drugset / Trial / NCT06046313
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficacy and safety of prolonged low-dose decitabine (10 days of 6mg/m2) plus venetoclax (3 weeks/cycle) regimen in primary diagnosed elderly or frail AML/ high-risk MDS.
Timeline
- Start
- 2023-10-19
- Primary completion
- 2025-10-19
- Completion
- 2026-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |